recombinant lamstatin and its CP17 peptide (Woolcock Institute of Medical Research/Cooperative Researh Centre for Asthma and Airways)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namerecombinant lamstatin and its CP17 peptide (Woolcock Institute of Medical Research/Cooperative Researh Centre for Asthma and Airways)
Drug Alias Namelymphangiogenesis inhibitor (Woolcock Institute of Medical Research/Cooperative Research Centre for Asthma and Airways)
ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionAngiogenesis inhibitors
TargetsUpdating
Therapy Area/IndicationsLymphangioleiomyomatosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWoolcock Institute Of Medical Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWoolcock Institute Of Medical ResearchCooperative Research Centre for Asthma and AirwaysAustralian Research Network
Active IndicationsN/A
Inactive IndicationsLymphangioleiomyomatosis

Other Information

ATC CodeN/A
Related LinksN/A